Advances in chemotherapy for HER2-negative metastatic breast cancer

被引：3
|
作者：
Mukai, Hirofumi [1 ]
Ito, Mayuko [1 ]
机构：
[1] Natl Canc Ctr Hosp East, Dept Breast & Med Oncol, 6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan
来源：
CHINESE CLINICAL ONCOLOGY | 2018年 / 7卷 / 03期
关键词：
Breast cancer; chemotherapy; quality of life (QOL); survival;
D O I：
10.21037/cco.2018.06.01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Metastatic breast cancer cannot be curable, but significant improvement in overall survival has been observed with the appearance of new agents. The purpose of treatment is to prolong survival and to improve quality of life by reducing cancer-related symptoms. To achieve these goals, individualized approach is required. Chemotherapy is used for patients with hormone receptor negative breast cancer or hormone receptor positive patients who have cancer-related symptoms. The choice of regimen (single-agent or a combination), selection of a specific therapy and the duration of treatment depend on multiple factors, including the tumor burden, general health status, prior treatments and toxicities, and patient preferences.
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Bevacizumab in the treatment of HER2-negative breast cancer
    Lorusso, Vito
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (04): : 813 - 821
  • [42] A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer
    Burstein, H. J.
    Storniolo, A. M.
    Franco, S.
    Forster, J.
    Stein, S.
    Rubin, S.
    Salazar, V. M.
    Blackwell, K. L.
    ANNALS OF ONCOLOGY, 2008, 19 (06) : 1068 - 1074
  • [43] Heterogeneity and prognostic characteristics of HER2-low breast cancer: A retrospective analysis of patients with HER2-negative metastatic breast cancer
    Lv, Huimin
    Yan, Min
    Zhang, Mengwei
    Niu, Limin
    Zeng, Huiai
    Sun, Huihui
    Zhao, Shengnan
    Wang, Jing
    CANCER RESEARCH, 2024, 84 (09)
  • [44] Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD
    Domchek, Susan M.
    Robson, Mark
    Im, Seock-Ah
    Senkus, Elzbieta
    Xu, Binghe
    Masuda, Norikazu
    Delaloge, Suzette
    Li, Wei
    Armstrong, Anne
    Conte, Pierfranco
    Bannister, Wendy
    Goessl, Carsten
    Runswick, Sarah
    Goel, Saurabh
    Tung, Nadine
    CANCER RESEARCH, 2018, 78 (04)
  • [45] Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer
    Yoshimoto, Masataka
    Takao, Shintaro
    Hirata, Masaru
    Okamoto, Yasushi
    Yamashita, Sumio
    Kawaguchi, Yoshihiro
    Takami, Makoto
    Furusawa, Hidemi
    Morita, Satoshi
    Abe, Chigusa
    Sakamoto, Junichi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (02) : 331 - 338
  • [46] Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer
    Masataka Yoshimoto
    Shintaro Takao
    Masaru Hirata
    Yasushi Okamoto
    Sumio Yamashita
    Yoshihiro Kawaguchi
    Makoto Takami
    Hidemi Furusawa
    Satoshi Morita
    Chigusa Abe
    Junichi Sakamoto
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 331 - 338
  • [47] Endocrine therapy or chemotherapy as first-line therapy in hormone receptorepositive HER2-negative metastatic breast cancer patients
    Jacquet, E.
    Lardy-Cleaud, A.
    Pistilli, B.
    Franck, S.
    Cottu, P.
    Delaloge, S.
    Debled, M.
    Vanlemmens, L.
    Leheurteur, M.
    Guizard, A. V.
    Laborde, L.
    Uwer, L.
    Jacot, W.
    Berchery, D.
    Desmoulins, I.
    Ferrero, J. M.
    Perrocheau, G.
    Courtinard, C.
    Brain, E.
    Chabaud, S.
    Robain, M.
    Bachelot, T.
    EUROPEAN JOURNAL OF CANCER, 2018, 95 : 93 - 101
  • [48] The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
    Wang, Wei
    Zhu, Tingting
    Chen, Hao
    Yao, Yongzhong
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (06): : 1673 - 1681
  • [49] The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
    Wei Wang
    Tingting Zhu
    Hao Chen
    Yongzhong Yao
    Clinical and Translational Oncology, 2023, 25 : 1673 - 1681
  • [50] Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
    Ni, M.
    Zhou, L.
    Lu, Y.
    Zhang, L.
    Li, X.
    Chen, M.
    Yang, A.
    Zhang, L.
    Xu, F.
    Yuan, Z.
    Wang, S.
    Shi, Y.
    An, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S1490 - S1490
12345